Meta-analysis: Serious adverse events in Crohn's disease patients treated with TNF-alpha inhibitors

Hepato-Gastroenterology

Volumn 60, Issue 126, 2013, Pages 1333-1342

  Zhang, Di ^a   Xiong, Bin ^a   Li, Xiaogai ^a   Xu, Tangpeng ^a   Yu, Mingxia ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Crohn's disease; Malignancy; Serious adverse events; Serious infection; TNF inhibitors

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSCESS; ARTHRALGIA; ARTICLE; CROHN DISEASE; DEATH; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; HUMAN; INFECTION; LUNG TUBERCULOSIS; META ANALYSIS; MULTIPLE SCLEROSIS; NEOPLASM; PERIANAL ABSCESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SERUM SICKNESS; SIDE EFFECT; SYSTEMATIC REVIEW; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; HUMANS; INFECTION; LYMPHOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885826115     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge121057     Document Type: Article

References (28)

1. Gonzalez S, Rodrigo L, Martinez-Borra J, et al.: TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. Amer J Gastroenterol 2003; 98:1101-1106. (Pubitemid 36733773)
2. Van Deventer SJ: Tumour necrosis factor and Crohn's disease. Gut 1997; 40:443-448.
3. Cohen RB and Dittrich KA: Anti-TNF therapy and malignancy - a critical review. Canadian J Gastroenterol 2001; 15:376-384. (Pubitemid 32684665)
4. Bongartz T, Sutton AJ, Sweeting MJ, et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275-2285. (Pubitemid 43736578)
5. D'Haens G: Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 2007; 56:725-732.
6. Biancone L, Calabrese E, Petruzziello C and Pallone F: Treatment with biologic therapies and the risk of cancer in patients with IBD. Nature Clinical Practice Gastroenterol Hepatol 2007; 4:78-91. (Pubitemid 46454794)
7. Moher D, Liberati A, Tetzlaff J and Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ (Clinical Research Ed) 2009; 339:b2535-b2535.
8. Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549. (Pubitemid 34621118)
9. Sands BE, Anderson FH, Bernstein CN, et al.: Infliximab maintenance therapy for fistulizing Crohn's disease. New England J Medicine 2004; 350:876-885. (Pubitemid 38252535)
10. Schreiber S, Khaliq-Kareemi M, Lawrence IC, et al.: Maintenance therapy with certolizumab pegol for Crohn's disease. New England J Medicine 2007; 357:239-250. (Pubitemid 47080388)
11. Sandborn WJ, Hanauer SB, Rutgeerts P, et al.: Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56:1232-1239. (Pubitemid 47300424)
12. Colombel JF, Sandborn WJ, Rutgeerts P, et al.: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132:52-65. (Pubitemid 46108762)
13. Colombel JF, Schwartz DA, Sandborn WJ, et al.: Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 2009; 58:940-948.
14. Watanabe M, Hibi T, Lomax KG, et al.: Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohn's Colitis 2012; 6:160-173.
15. Rutgeerts P, Van Assche G, Sandborn WJ, et al.: adalimumab induces and maintains mucosal healing in patients with Crohn's disease: Data from the EXTEND Trial. Gastroenterology 2012; 142:1102-1111.
16. Lemann M, Mary JY, Duclos B, et al.: Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130:1054-1061.
17. Colombel JF, Sandborn WJ, Reinisch W, et al.: Infliximab, azathioprine, or combination therapy for Crohn's disease. New England J Medicine 2010; 362:1383-1395.
18. Sandborn WJ, Feagan BG, Stoinov S, et al.: Certolizumab pegol for the treatment of Crohn's disease. New England J Medicine 2007; 357:228-238. (Pubitemid 47080387)
19. Sandborn WJ, Feagan BG, Radford-Smith G, et al.: CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004; 53:1485-1493. (Pubitemid 39265271)
20. Sandborn WJ, Feagan BG, Hanauer SB, et al.: An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120:1330-1338. (Pubitemid 32322306)
21. Allez M, Vermeire S, Mozziconacci N, et al.: The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Alimentary pharmacology & therapeutics 2010; 31:92-101.
22. Huang ML, Ran ZH, Shen J, et al.: Efficacy and safety of adalimumab in Crohn's disease: meta-analysis of placebo-controlled trials. Journal of digestive diseases 2011; 12:165-172.
23. Humira™ (Adalimumab), DN0735V7 CR22-05126. 2002;16p.
24. Bernstein CN, Blanchard JF, Kliewer E and Wajda A: Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91:854-862. (Pubitemid 32173312)
25. Lakatos PL and Miheller P: Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? Current drug targets 2010; 11:179-186.
26. Rutgeerts P, Van Assche G and Vermeire S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126:1593-1610. (Pubitemid 38649876)
27. Lewis JD, Bilker WB, Brensinger C, et al.: Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121:1080-1087. (Pubitemid 33022087)
28. Peyrin-Biroulet L, Deltenre P, de Suray N, et al.: Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6:644-653. (Pubitemid 351783447)